Background-Recently published analysis of contemporary atrial fibrillation (AF) cohorts showed an association between digoxin and increased mortality and hospitalizations; however, other studies have demonstrated conflicting results. Many AF cohort studies did not or were unable to examine racial differences. Our goal was to examine risk factors for hospitalizations and mortality with digoxin use in a diverse real-world AF patient population and evaluate racial differences. Methods and Results-We performed a retrospective cohort analysis of claims data for Medicaid beneficiaries, aged 18 to 64 years, with incident diagnosis of AF in 2008 with follow-up until December 31, 2009. We created Kaplan-Meier curves and constructed multivariable Cox proportional hazard models for mortality and hospitalization. We identified 11 297 patients with an incident diagnosis of AF in 2008, of those, 1401 (12.4%) were on digoxin. Kaplan-Meier analysis demonstrated an increased risk of hospitalization with digoxin use overall and within race and heart failure groups. In adjusted models, digoxin was associated with an increased risk of hospitalization (adjusted hazard ratio, 1.54; 95% confidence interval, 1.39-1.70) and mortality (adjusted hazard ratio, 1.50; 95% confidence interval, 1.05-2.13). Overall, blacks had a higher risk of hospitalization but similar mortality when compared with whites regardless of digoxin use. We found no significant interaction between race and digoxin use for mortality (P=0.4437) and hospitalization (P=0.7122). Conclusions-Our study demonstrates an overall increased risk of hospitalizations and mortality with digoxin use but no racial/ethnic differences in outcomes were observed. Further studies including minority populations are needed to critically evaluate these associations. (Circ Arrhythm Electrophysiol. 2017;10:e004573.
A trial fibrillation (AF) is the most common cardiac arrhythmia and significantly increases the risk of morbidity and mortality as well as associated healthcare costs. 1 The lifetime risk of AF is 1 in 4 among patients aged >40 years and 1 in 6 among patients without congestive heart failure (HF) or myocardial infarction. 2 The prevalence of AF in the United States is estimated at 3.3 million patients (including patients with atrial flutter), and this number is projected to increase significantly by 2025. 3, 4 An estimate of national incremental cost of AF ranges between $6.0 and $26.0 billion with hospitalizations being the primary driver of cost. 4 Direct medical costs were estimated to be 73% higher in patients with AF than in those without.
Although the risk of AF is estimated to be lower among blacks than among whites, 5, 6 the burden of AF among blacks remains substantial, with 1 in 9 diagnosed before 80 years of age. 7 Lower prevalence estimates may also represent underdiagnosis in this population. A recent analysis of the ORBIT-AF cohort (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) showed black patients with AF were more symptomatic, less likely to receive rhythm control interventions, and had the lowest rate of anticoagulation use for stroke prevention. 8 Recently published retrospective, prospective, and post hoc analysis of randomized controlled trials studies of AF cohorts showed digoxin to be associated with increased mortality among patients with HF and those without. [9] [10] [11] [12] [13] However, various studies have demonstrated conflicting results. [14] [15] [16] In 
Digoxin Use in Atrial Fibrillation
Studies of other cardiovascular diseases have demonstrated not only differences in prevalence, morbidity, mortality, and risk factors 22 but also effectiveness of therapeutic agents and medication side effects by race/ethnicity. [23] [24] [25] For example, fixed-dose combined isosorbide dinitrate/hydralazine seems to be more efficacious among black patients with HF, 25 whereas blacks with hypertension may respond less well than whites to angiotensin-converting enzyme inhibitors. 26, 27 Analysis of the SOLVD Prevention and Treatment trials (Studies of Left Ventricular Dysfunction) demonstrated that enalapril was associated with a decreased risk of hospitalization for HF and significant reductions in blood pressure among white patients but showed no significant benefits in black patients. 28, 29 Studies have also shown that the risk of angiotensin-converting enzyme inhibitorsinduced angioedema to be more common among blacks than among whites. 29 However, in the absence of data among blacks, current guidelines for HF management based on trial data derived from predominantly young, white, male study populations continue to dictate therapeutic options for black patients. 29 There are also little data on differential responses to therapy across socioeconomic gradients or allostatic load.
Therefore, the aim of this study was to examine the effect of digoxin on mortality and hospitalizations among patients with AF in a low-income, high-minority Medicaid patient population and to use Medicaid claims data to understand racial differences in this association between digoxin therapy and outcomes in patients with AF. The Medicaid population by definition consists of socioeconomically disadvantaged patients and includes a large minority population who are under-represented in historical and contemporary AF clinical trials and registries.
Methods

Study Design
A retrospective cohort design was utilized to identify and analyze claims data for Medicaid beneficiaries. The study population was drawn from a sample of available Medicaid claims data from 27 states (Alabama, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, and Washington) and the federal district (Washington, DC). Patients from these jurisdictions make up 80% of all people enrolled in Medicaid, and 90% of all black and Hispanic or Latino Medicaid enrollees in the entire US California was excluded from our analyses because of the unavailability of mortality data in our claims data set.
Study Population
We identified 11 297 patients with an incident diagnosis of AF, continuously enrolled for at least 12 Patients aged ≥65 years who were also eligible for Medicare were excluded because of incomplete information on medication claims not available in our Medicaid data set. We also excluded patients with digoxin use before his or her index date of AF diagnosis. Institutional review board approval for this study was obtained from the Morehouse School of Medicine, and all patient records/information were anonymized and deidentified before analysis.
Variables
Our primary independent variable/predictor of interest was digoxin use. Digoxin use was defined as ever-receiving digoxin after AF diagnosis. We also sought to evaluate interactions between race/ ethnicity and digoxin use. Race/ethnicity was determined based on entries from administrative Medicaid files, and this has been shown to be highly correlated with self-identification of race/ ethnicity. 30 Our primary dependent variable (outcome) was all-cause mortality (ie, survival time-calculated from the time of incident AF diagnosis to the time of death). Death data were obtained from reported discharge status information available in the Medicaid claims data. Our secondary outcome was time to first hospitalization found in the inpatient file in the Medicaid claims data.
Other independent variables or covariates of interest included demographic and clinical variables, including age, sex, cardiovascular diseases (acute myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, intracranial hemorrhage, peripheral arterial disease, and valvular heart disease), ventricular arrhythmias (ventricular tachycardia or fibrillation), cardiac procedures (percutaneous coronary intervention or coronary artery bypass surgery), other cardiovascular risk factors (HF, hypertension, diabetes mellitus, and dyslipidemia), and other coexisting medical illnesses (dementia, depression, thyroid disease, gastrointestinal bleeding, other bleeding, cancer, lung disease, liver disease, chronic kidney disease, and end-stage renal disease), and treatments (β-blocker, amiodarone, warfarin, and ablation therapy). All comorbid conditions were identified using International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes as in a previously published article. 11 All covariates were identified during the study follow-up period between 2008 and 2009. We controlled for the variables HF, hypertension, diabetes mellitus, ischemic stroke, transient ischemic attack, and arterial thromboembolism/ischemia within the composite variable, CHADS2 score (congestive heart failure, hypertension, age ≥75 years, diabetes, and stroke history), which is a validated predictor of thromboembolic risk. 31, 32 Patients aged ≥75 years were not included in our CHADS2 calculation as our study population consisted
WHAT IS KNOWN
• Recent studies of atrial fibrillation cohorts have demonstrated an association between digoxin and adverse outcomes among patients with and without heart failure.
• The adverse outcomes seen with digoxin use in atrial fibrillation cohorts has not been fully evaluated in minority patients.
WHAT THE STUDY ADDS
• Our study confirms that digoxin use is associated with increased risk of hospitalization and mortality in a low-income, high-minority patient population (who are underrepresented in historical and contemporary atrial fibrillation clinical trials and registries).
• Race did not appear to modify the effect of digoxin use on outcomes in patients with atrial fibrillation. of adults <65 years. The variables age, sex, race, acute myocardial infarction, warfarin, amiodarone, and β-blocker use were included as individual variables in our multivariable model. To control for all other variables, we created a logistic regression model to calculate a propensity score, which was then used in our analysis as a covariate. A propensity score analysis uses a single composite number to control for multiple variables simultaneously. 33, 34 This method has been proven to generate reliable effect estimates controlling for each individual's clinical and personal characteristics, which might predispose him or her to receive a digoxin prescription and which might introduce systematic bias into the outcomes analysis. 35 Propensity scores have been used in various pharmacoepidemiologic analyses of healthcare claims data, 36 including observational studies seeking to draw causal inferences. 37 
Data Analysis
We calculated descriptive statistics, proportions, and χ 2 tests based on data distribution. We evaluate variables for adherence to the proportional hazards assumptions and generated Kaplan-Meier curves for digoxin use for the entire study population and stratified by race/ethnicity. Given patients with HF likely have a unique benefit of digoxin use compared with those without, we also created Kaplan-Meier curves stratified by HF diagnosis. We constructed crude and adjusted Cox proportional hazard regression models to evaluate the association between digoxin use and survival while adjusting for potential confounders. Variables were included in the final model based on bivariate analysis and previous literature identifying it as a potential confounder. A composite propensity score variable was used in controlling for multiple covariates. To evaluate variations in the effect of digoxin within each race/ethnic group, we assessed for interaction between digoxin use and race/ethnicity.
Missing variables were excluded from analysis. All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC) procedures, and data were evaluated at the 0.05 significance level.
Results
Of 11 297 patients with incident AF included in our study, we found 12.4% had ever received digoxin. Among patients on digoxin, 65% had a diagnosis of HF. Our study population included 51% whites, 29% blacks, and 6% Hispanics. Patients aged 50 to 64 years represented 67% of the entire sample and made up 72% of all patients who perceived digoxin (Table 1) . Ventricular arrhythmias, ablation therapy, β-blocker use, and amiodarone use were more common among patients who received digoxin therapy.
Mortality
Overall Kaplan-Meier curves showed a modest increased risk of mortality with digoxin therapy (Figure 1 ) compared with patients who did not receive digoxin (log-rank test=0.0107).
When stratified by race, blacks and patients of other race also had a statistically significant higher risk of mortality with digoxin use (log rank=0.0422) before controlling for covariates. We were unable to estimate the median survival time since more than half the population were still alive at the end of the study period. Median survival (6-month) and 1-year survival were 98% and 94%, respectively, among digoxin users and 98% and 96%, respectively, among patients not on digoxin therapy. Kaplan-Meier analysis showed no significant difference in mortality when stratified by HF diagnosis.
In crude models, digoxin use was associated with a 36% increase in the instantaneous risk of death (adjusted hazard ratio [aHR], 1.36; 95% CI, 1.07-1.72), age ≥50 years, history of acute myocardial infarction, and CHADS2 score of ≥2 were associated with increased hazard of death (Table 2 ). In our propensity score-adjusted model, digoxin use was associated with a 50% increase in the risk of death (aHR, 1.50; 95% CI, 1.05-2.13). In addition, age ≥50 years, acute MI, and CHADS2 score of ≥2 remained significantly associated with an increased risk of mortality (Table 2 ). Sex and racial differences were not statistically significant after adjusting for covariates. We also assessed for interaction between race and digoxin on mortality and found no statistically significant interaction (blacks compared with whites, P value for interaction 0.4437). In stratified analysis, digoxin use was not significantly associated with mortality among blacks or whites (Table I in 
Hospitalization
Kaplan-Meier curves for the entire population showed digoxin therapy to be significantly associated with an increased risk of hospitalization ( Figure 2 ) compared with patients who did not receive digoxin (log-rank test, <0.0001). The median time to first hospitalization was 3.2 months among patients on digoxin therapy and 11 months among patients not on digoxin.
When stratified by race, digoxin use demonstrated a statistically significant higher risk of hospitalization in all racial groups except among patients of other race ( Figure 3A through  3D) . When stratified by digoxin use, blacks were at a higher risk of hospitalization compared with Hispanic and white patients among digoxin users and nonusers ( Figure 4A and 4B). Among blacks, whites, Hispanics, and patients of other race, the median time to first hospitalization was 2.7, 3.5, 4.3, and 5.5 months for digoxin users versus 9, 12, 13, and 8.5 months for digoxin nonusers, respectively. Figure 5A and 5B shows digoxin use was significantly associated with increased risk of hospitalization among patients with and without HF. Table 3 shows the unadjusted HR and aHR for hospitalization. All HRs (or instantaneous risk of hospitalization) >1.0 indicate a shorter time to hospitalization and those <1.0 denote a longer time to hospitalization. In propensity *Adjusted for propensity score (includes unstable angina, intracranial hemorrhage, valvular heart disease, ventricular arrhythmias, dyslipidemia, dementia, depression, thyroid disease, gastrointestinal bleed, other bleed, cancer, lung disease, liver disease, percutaneous coronary intervention, coronary artery bypass surgery, ablation procedure, chronic kidney disease, and end-stage renal disease), warfarin, amiodarone, β-blocker use, and all variables are listed in the table. Digoxin Use in Atrial Fibrillation score-adjusted models, digoxin use was associated with a 54% increase in the risk of hospitalization (aHR, 1.54; 95% CI, 1.39-1.70). Patients aged 50 to 64 years and those aged 30 to 39 years were less likely to be hospitalized when compared with younger patients (aged, 18-29 years). Men, blacks, and patients of other race had a higher risk of hospitalization, but Hispanic patients were less likely to be hospitalized when compared with whites. CHADS2 score of ≥2 was associated with an increased likelihood of hospital admission. We also assessed for effect modification by race and found the interaction term between digoxin use and race was not significant (blacks compared with whites, P value for interaction 0.7122). The HR estimates for digoxin use were similar for whites (aHR, 1.74; 95% CI, 1.49-2.03) and black (aHR, 1.62; 95% CI, 1.30-2.04) in stratified analysis (Table I in the Data Supplement).
Discussion
Our study results are consistent with the results of previous studies, which have demonstrated an increased mortality risk associated with digoxin use among patients with AF. 11, 38 However, many previous studies could not be applied specifically to the black, socioeconomically disadvantaged, or other minority populations. Our study is unique, in that it included a large proportion of blacks, whereas minimizing the socioeconomic differences between black and white patients (because of low-income eligibility requirements to enroll in Medicaid). It also reflects real-world behaviors with regard to medication access and compliance, with none of the observation bias inherent in controlled trials. The differential effect of race on mortality with digoxin therapy is an issue of concern. Mathew et al 39 showed no racial differences in the risk of death or hospitalization with digoxin use among patients with HF. An analysis of a large inpatient hospitalization database also showed an increased risk of in-hospital mortality among blacks with AF compared with whites. 40 Based on our findings, blacks did not seem to have a higher risk of mortality with digoxin use in stratified models, but digoxin use was associated with hospitalizations in both blacks and white patients. This increased risk may be, in part, because of disparities in early recognition and initiation of recommended therapy and interventions among black patients. Naderi et al 41 demonstrated racial disparities in rhythm control interventions (such as ablation procedure or cardioversion), for AF and increased odds of in-hospital mortality among black patients on digoxin therapy for AF compared with whites. A recent analysis of the ORBIT-AF cohort demonstrated that black patients were less likely to receive rhythm control interventions and had the lowest rate of anticoagulation use for stroke prevention. 8 It has been suggested that the observed low prevalence of AF among black patients may be explained by unequal access to healthcare and the possibility of a higher prevalence of disease subtypes, such as paroxysmal AF among this patient population leading to more missed diagnosis. 22 On-going racial stress and allostatic load may also be contributing to increased risk of adverse outcomes among blacks compared with whites, and studies have shown this to be higher among the former. 42, 43 In addition, blacks have higher rates cardiovascular disease-related morbidity and mortality 44 and this may magnify the side effect profile of digoxin and possibly minimize therapeutic effect. Overall, we found an increased risk of hospitalizations among black patients independent of digoxin use after adjustments for confounding. Our findings suggest no significant interaction between race and digoxin use. This may be, in part, because of inadequate follow-up time given our study was restricted to a 1-year follow-up period post-AF diagnosis. In addition, we included only patients without an AF diagnosis within the first 3 months of the study start date because of the limited follow-up period (1 year), as such, this limited time may not have been enough to identify all patients with incident AF.
Previous analysis of the DIG trial (Digitalis Investigation Group) showed that digoxin reduced mortality and risk of hospitalizations at low concentrations and HF hospitalizations at higher concentrations among HF patients without any effect on mortality. 45 However, multiple studies of digoxin use in AF cohorts have demonstrated the contrary, among patients with and without HF. 11, 13, 17 Others have shown that adverse effects of digoxin with AF patients were limited to patients without HF and ejection fraction >40%. 15 The relationship between HF and AF and its association with digoxin use remains unclear.
In our study, when stratified by HF, Kaplan-Meier analysis showed that digoxin use was associated with increased risk of hospitalization among patients with and without HF, but no effect was seen with mortality on stratification.
We were unable to adjust for ejection fraction as this was not available in our data set. Our study is limited in generalizability to individuals who meet both income and categorical eligibility criteria to enroll in Medicaid. Therefore, it included more racial/ethnic minorities and women, relative to the general US population, as well as more patients who would meet criteria for permanent and total disability (since the data came from years before Medicaid expansion under the Affordable Care Act). Because we had no access to Medicare part D data, we excluded patients who had dual Medicare/Medicaid enrollment, and therefore the population studied was younger (<65 years) than would be expected for a cohort of patients with AF. Our data were subject to the limitations of administrative claims data, including the difference between billed diagnoses and those shown in the clinical record. We had no access to detailed clinical data such as echocardiography, left ventricular ejection fraction, and renal function (including serum creatinine and estimated glomerular filtration rate). If mortality occurred We were unable to evaluate on-treatment events, given difficulties associated with estimating that a given patient was on digoxin therapy at the time of an event in our data set. Digoxin use was defined as ever-receiving digoxin after AF diagnosis. We did not exclude patients who used digoxin infrequently from our analysis, given that infrequent medication refills is what occurs in real-world patients. In addition, including these patients without high medication adherence rates is more likely to limit our ability to detect a difference when compared with patients who had never been on digoxin therapy, therefore, making our estimates more conservative (ie, any use, including infrequent use, has an impact on short-term clinical outcomes). In addition, data set limitations only allow us to identify the time period within which a prescription for digoxin was filled, but we cannot ascertain the exact date the medication was started by a patient given our information is obtained from claims data. Starting our follow-up time from the date of AF diagnosis attempts to evaluate each patient using a prespecified standard. However, it is possible that some patients started digoxin on the day of diagnosis and others received digoxin within weeks or months after diagnosis, but we could not ascertain this.
However, our data did consist of a large sample of Medicaid claims from 27 states and the District of Columbia, which represent all paid claims on 80% of all US Medicaid enrollees and 90% of minority Medicaid enrollees in the United States This allows for a real-world analysis of health outcomes among minorities (especially blacks), who are under-represented in most AF clinical trials and registries, whereas minimizing socioeconomic differences between racial-ethnic groups, because of Medicaid enrollment criteria.
Digoxin is associated with increased risk of hospitalization and mortality in a real-world population of patients with AF, patients with black, and patients being at a higher risk of hospitalization independent of digoxin use. The association of digoxin use with hospitalizations and mortality, however, was not modified by race. Our study adds to the growing body of work examining risk factors for adverse outcomes among patients with AF and the specific impact on minority patients. These findings occur in In summary, digoxin therapy in patients with AF may increase the risk of hospital admissions contrary to its presumed benefit. Physicians need to assess the risk-benefit ratio in individual patients before initiating digoxin therapy. Additional prospective studies are needed to critically examine the relationship between digoxin and clinical outcomes and to further evaluate the effect that race/ethnicity may play in patient outcomes. To this end, AF registries specifically targeting minority populations may be needed. CI indicates confidence interval; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes, stroke history; and Ref, reference.
*Adjusted for propensity score (includes unstable angina, intracranial hemorrhage, valvular heart disease, ventricular arrhythmias, dyslipidemia, dementia, depression, thyroid disease, gastrointestinal bleed, other bleed, cancer, lung disease, liver disease, percutaneous coronary intervention, coronary artery bypass surgery, ablation procedure, chronic kidney disease, and end-stage renal disease), warfarin, amiodarone, β-blocker use, and all variables are listed in the table.
